At AcuFast, we focus on creating realized genetic value, which is built on three critical pillars: our genetic portfolio, commercial testing platform, and technology platform. Today, we'll take a closer look at our commercial testing platform and its crucial role in validating genetic progress.
The success of any genetic improvement program hinges on the validation of its progress. AcuFast's commercial testing platform is designed precisely for this purpose, ensuring that our program – and in turn, yours – achieves optimal success.
AcuFast utilizes test herds for both terminal and maternal lines, validating our purebred lines as well as crossbred performance. This comprehensive approach ensures that we assess the full spectrum of performance, allowing for the most efficient genetic progress.
Our Commercial Test Herd (CTH) measures, evaluates, and selects traits based on their true system value, with commercial performance driving the selection of purebred traits.
Sire Selection Process
The selection of sires for the test herd begins at the nucleus level. We assess their performance potential based on key commercial production traits using an index. Top-indexing sires are then tested through the CTH. For each sire, we conduct sire line trials, precisely managing factors such as nutrition, stocking density, and ventilation that could influence the performance of their offspring.
This rigorous testing in a commercial environment allows us to accurately gauge genetic performance. The sires that excel in both the initial index and commercial performance are selected to become AcuFast sires.
The Importance of Phenotypic Data